肺纤维化治疗要趁早，如何做好早期识别和评估？

妙手医生

发布时间：2023-09-20阅读量：1216次阅读

温馨提示：以下内容是针对圆心大药房网上药店展示的商品进行分享，方便患者了解日常用药相关事项。请患者在用药时（处方药须凭处方）在药师指导下购买和使用。

参考文献：

[1].潘锋.间质性肺疾病早诊早治仍极具挑战性——访中日友好医院呼吸与危重医学科代华平教授[J]. 2019,26(7).

[2].Raghu G, Remy-Jardin M, Myers JL, et al.Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68.

[3].Raghu G, Remy-Jardin M, Richeldi L,et al.Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47.

[4].Richeldi L, Costabel U, Selman M,et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011 Sep 22;365(12):1079-87.

[5].Richeldi L, du Bois RM, Raghu G,et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2071-82.

[6].Distler O, Highland KB, Gahlemann M, et al.Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 Jun 27;380(26):2518-2528.

[7].Flaherty KR, Wells AU, Cottin V,et al.Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019 Oct 31;381(18):1718-1727.

审批码：PC-CN-103881 有效期是2024-3-15

*此文仅用于向医学人士提供科学信息，不代表本平台观点

[8].中国医师协会风湿免疫科医师分会风湿病相关肺血管/间质病学组. 2018中国结缔组织病相关间质性肺病诊断和治疗专家共识[J].中华内科杂志.2018,57(8):558-565.

以上内容仅供参考